Ft. Lauderdale, Florida – August 18, 2005 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM - News), one of the fastest growing companies in the EDC marketplace, announced today that Asthmatx, Inc. (Mountain View, CA) has selected its TrialMaster Electronic Data Capture (EDC) and Trial Management Solution for conducting its IDE clinical trial of the Alair System for the treatment of asthma.  Asthmatx, a medical device company, is developing a novel investigational device-based procedure called Bronchial Thermoplasty™ for the treatment of asthma.  Asthmatx conducted a thorough evaluation of leading EDC vendors before selecting OmniComm Systems’ unique EDC solution.

TrialMaster is a flexible and easy to use web-based Electronic Data Capture and trial management solution that optimizes the efficiency and accuracy of data collection while reducing the costs associated with paper-based clinical trials. With the TrialMaster solution, medical device companies such as Asthmatx can conduct clinical trials with electronically end-to-end high quality data collection, data management, and efficient trial management.

“Asthmatx requires complete and accurate collection of clinical research data and the ability to analyze the data in the shortest time possible after a database “freeze” or lock. The capabilities of OmniComm’s’ EDC solution promises to save Asthmatx time and money”, said Glendon E. French, President and CEO of Asthmatx.  “We selected the TrialMaster solution because of its ease of use and flexible structure. The integrated platform should enable Asthmatx to save valuable time and provide control over critical trial processes”.

“It is a tribute to TrialMaster and our team that Asthmatx has chosen TrialMaster as its EDC solution,” stated Cornelis Wit, President and CEO of OmniComm.   “We are proud to be partnering with Asthmatx to support its data collection needs.  Our TrialMaster solution provides companies such as Asthmatx with more efficient resource management and significant time and cost savings, bringing new treatment options to market more quickly and efficiently.”

About Asthmatx, Inc.

Asthmatx designs, develops and manufactures medical devices for the treatment of asthma, a condition that affects over 20 million people in the United States. Asthmatx has developed the Alair System, which consists of a single-use treatment catheter that is attached to a controller that delivers energy to airway walls during a bronchoscopic procedure known as Bronchial Thermoplasty™.  The Alair System provides a novel investigational treatment approach to asthma that applies controlled heat to the airway wall to reduce the amount of airway smooth muscle and restrict its ability to narrow the airway. Asthmatx is currently conducting a pivotal study investigation to establish the safety and efficacy of the Alair System for the treatment of asthma (AIR2Trial.com).

CAUTION: The Alair System is an Investigational device.  It is limited by Federal (United States) law to investigational use.  To be used by Qualified Investigators only. 

About OmniComm Systems, Inc.

OmniComm Systems, Inc. is one of the fastest growing companies in the EDC market place targeting its product TrialMaster to the pharmaceutical, medical device and biotechnology companies as well as CRO’s.  OmniComm’s growing base of satisfied customers is a direct result of OmniComm’s employee’s commitment to on-time, quality and within budget performance. 

The TrialMaster system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.

For more info, please email info@omnicomm.com

Back